Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2013
T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomesIvan Martinez-Forero, Arantza Azpilikueta, Elixabet Bolaños-Mateo, et al.
Cancer Discovery|October 24, 2015
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic CellsAlfonso R Sánchez-Paulete, Francisco J Cueto, María Martínez-López, et al.
Oncoimmunology|January 4, 2018
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB)Arantza Azpilikueta, Elixabet Bolaños, Valerie Lang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2013
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse modelAizea Morales-Kastresana, Miguel F Sanmamed, Inmaculada Rodriguez, et al.
Cancer Immunology, Immunotherapy : CII|March 26, 2010
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organJuan Dubrot, Francisca Milheiro, Carlos Alfaro, et al.
Oncoimmunology|March 5, 2016
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanismSara Labiano, Asis Palazón, Elixabet Bolaños, et al.
Cancer Discovery|June 22, 2012
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapyAsís Palazón, Iván Martínez-Forero, Alvaro Teijeira, et al.
Oncoimmunology|January 4, 2018
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor modelsKatherine E Lewis, Mark J Selby, Gregg Masters, et al.
Cancer Immunology Research|January 14, 2014
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitorMargaret K Callahan, Gregg Masters, Christine A Pratilas, et al.
Blood Advances|July 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FLIsil Altintas, Christopher Morehouse, Elena Favaro, et al.
Pageof 4